Principal Results
colorectal cancer
COLORECTAL CANCER
The strengths of this study include the clinical importance of an app for supporting patients with GC and the theory-derived intervention as well as the methodological rigor in collecting and analyzing data. The MGCS program is the first expert-led app-based program designed in China for patients with GC receiving chemotherapy. The MGCS program illustrates how an app-based support program can be incorporated into routine care to promote health outcomes for patients with GC receiving chemotherapy.Our trial shows that the MGCS program significantly decreased the uncertainty in patients with GC at 24 weeks. This is consistent with that reported in another study, which found that a mobile navigation program significantly decreased the uncertainty in patients with colorectal cancer [Our results show that the MGCS program significantly improved the QoL of patients with GC at 24 weeks. Minimally important clinical differences with values over 3-7 in the FACT-G scale have been established as clinically meaningful improvements in QoL [Our trial shows that the MGCS program did not significantly improve the symptom distress and social support of patients with GC at 24 weeks. In the MGCS program, symptom management strategies were provided, but the practices of the strategies were not tracked or monitored. Patients with GC may not practice these strategies or may get tired of doing the same exercises strategies over time [We found no significant differences in any of the health outcomes between the intervention and control groups at 12 weeks. During early chemotherapy cycles, patients with GC experience high levels of physical and psychological distress, which may limit their ability or desire to read, interact with others, and practice coping strategies [